Next Article in Journal
Beyond Chelation: EDTA Tightly Binds Taq DNA Polymerase, MutT and dUTPase and Directly Inhibits dNTPase Activity
Previous Article in Journal
Status of Plant Protein-Based Green Scaffolds for Regenerative Medicine Applications
Open AccessArticle

YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine

1
The Key Laboratory of Traditional Chinese Medicine Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, Yantai 264003, China
2
Key Laboratory of Tumor Molecular Biology in Binzhou Medical University, Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai 264003, China
*
Authors to whom correspondence should be addressed.
Biomolecules 2019, 9(10), 620; https://doi.org/10.3390/biom9100620
Received: 8 September 2019 / Revised: 7 October 2019 / Accepted: 14 October 2019 / Published: 17 October 2019
Nuciferine, a major aporphine alkaloid constituent of lotus leaves, is a raw material for obesity treatment. Extensive studies have revealed that obesity is associated with pancreatic cancer (PC). However, it has not been clarified whether nuciferine could be used in PC treatment or prevention. Here, we show that nuciferine could enhance the sensitivity of PC cells to gemcitabine in both cultured cells and the xenograft mouse model. The mechanism study demonstrated that nuciferine induced YAP Ser127 phosphorylation [pYAP(Ser127)] through AMPK-mediated 3-hydroxy-3-methyl-glutaryl-coA reductase (HMGCR) downregulation. Remarkably, wild-type YAP overexpression or YAP Ser127 mutant could resist to nuciferine and no longer sensitize PC cells to gemcitabine. Knockdown of AMPK attenuated pYAP(Ser127) induced by nuciferine. Moreover, knockdown of AMPK reversed nuciferine-mediated HMGCR downregulation. Notably, HMGCR inhibiting could restrain YAP by phosphorylation Ser 127, and therefore enhance the efficiency of gemcitabine in PC cells. In line with this consistent, overexpression of HMGCR reduced growth inhibition caused by nuciferine and/or gemcitabine treatment in PC cells. In summary, these results provide an effective supplementary agent and suggest a therapeutic strategy to reduce gemcitabine resistance in PC. View Full-Text
Keywords: Nuciferine; Yes-associated protein; AMP-activation protein kinase; 3-hydroxy-3-methyl-glutaryl-coA reductase; gemcitabine; pancreatic cancer Nuciferine; Yes-associated protein; AMP-activation protein kinase; 3-hydroxy-3-methyl-glutaryl-coA reductase; gemcitabine; pancreatic cancer
Show Figures

Graphical abstract

MDPI and ACS Style

Zhou, L.; Wang, Q.; Zhang, H.; Li, Y.; Xie, S.; Xu, M. YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine. Biomolecules 2019, 9, 620.

AMA Style

Zhou L, Wang Q, Zhang H, Li Y, Xie S, Xu M. YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine. Biomolecules. 2019; 9(10):620.

Chicago/Turabian Style

Zhou, Ling; Wang, Qiaoyun; Zhang, Han; Li, Youjie; Xie, Shuyang; Xu, Maolei. 2019. "YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine" Biomolecules 9, no. 10: 620.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop